New drug combo shows promise for Hard-to-Treat breast cancer
NCT ID NCT07413601
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether adding the experimental drug QL1706 to standard platinum chemotherapy helps people with advanced triple negative breast cancer live longer without their disease getting worse. About 78 adults who have already had one or two prior treatments will be randomly assigned to receive either the drug combo or chemo alone. The study aims to see if the combination improves outcomes like tumor shrinkage and progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QL1706 (iparomlimab and tuvonralimab) plus platinum chemotherapy (cisplatin or carboplatin)
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced triple negative breast cancer who have already tried other therapies.
- What could go wrong
- This is an early Phase 2 trial with only 78 participants, so results may not apply to everyone. The combination may cause significant side effects and may not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
No. 17 Panjiayuan Nan Li, Chaoyang District, Beijing
Beijing, Beijing Municipality, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.